Intuitive Surgical, Inc. (ISRG)
|Net Income (ttm)||1.69B|
|Day's Range||337.44 - 343.26|
|52-Week Range||217.67 - 362.34|
|Price Target||353.77 (+4.2%)|
|Est. Earnings Date||n/a|
Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head a... [Read more...]
In 2020, ISRG's revenue was $4.36 billion, a decrease of -2.68% compared to the previous year's $4.48 billion. Earnings were $1.06 billion, a decrease of -23.11%.Financial Statements
According to 20 analysts, the average rating for ISRG stock is "Buy." The 12-month stock price forecast is 353.77, which is an increase of 4.16% from the latest price.
Tech Takes A Break But S&P 500 Rises; Mosaic, Intuitive Surgical, And Home Construction In Focus
Tech Takes Break But S&P 500 Powers Higher; Mosaic, Intuitive Surgical, And Home Construction In Focus Investor's Business Daily has been helping people invest smarter results by providing exclusive sto...
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
These reliable healthcare companies have a lot to offer investors.
Intuitive Surgical Inc (NASDAQ: ISRG) reported Q3 adjusted EPS of $1.19, slightly ahead of the consensus of $1.17. It reported revenues of $1.403 billion, +30% Y/Y, marginally ahead of Wall Street estim...
Better-than-expected revenue and earnings are just part of the story for Intuitive.
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 0.00% and 0.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Moves reflect growth and help advance minimally invasive care Moves reflect growth and help advance minimally invasive care
SUNNYVALE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today an...
Intuitive Surgical (ISRG) has been struggling lately, but the selling pressure may be coming to an end soon.
ISRG is set to give its latest quarterly earnings report on Tuesday, 2021-10-19. Here's what investors need to know before the announcement.
PRECIsE Clinical Study Preliminary Results Favorable for Intuitive's Ion Endoluminal System for Peripheral Nodule Lun...
SUNNYVALE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the rele...
Intuitive Surgical, a fast growing robotic surgical platform company, is scheduled to report its Q3 2021 results on Tuesday, October 19. We expect Intuitive Surgical to likely to report mixed earnings w...
Tesla's in the fast lane but these innovators could have more in the tank.
Intuitive Surgical, Inc. (ISRG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The answer may depend on each investor's time horizon.
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
This medical device manufacturer has been a long-term market beater.
An analyst's downgrade following downbeat comments from management has pushed the robotic surgery company's stock down to an attractive price.
Intuitive Surgical, Inc. (ISRG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is (ISRG) Outperforming Other Medical Stocks This Year?